Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment

PR Newswire11-07

Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market YOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481902628?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WN5J50u_wJ0hC0TAl9bSHw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/2083d11d0f214568d3e3d481af0f5046","is_english":true,"pubTime":"2024-11-07 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481902628","market":"us","top_or_hot":-1,"title":"Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment","media":"PR Newswire","content":"<div>\n<p>Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market \nYOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/limacas-precision-gi-granted-cms-130000227.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance_sg","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLimaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/limacas-precision-gi-granted-cms-130000227.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market \nYOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/limacas-precision-gi-granted-cms-130000227.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://finance.yahoo.com/news/limacas-precision-gi-granted-cms-130000227.html","article_id":"2481902628","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WN5J50u_wJ0hC0TAl9bSHw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/2083d11d0f214568d3e3d481af0f5046"],"rights":{"source":"yahoofinance_sg","url":"https://finance.yahoo.com/news/limacas-precision-gi-granted-cms-130000227.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481902628","pubTimestamp":1730984400,"sourceInfo":{"source_id":"yahoofinance_sg","name":"Yahoo Finance"},"weMediaInfo":null,"summary":"Precision-GI FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market. YOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services  has granted transitional pass-through  payment for Limaca Medical Ltd. 's Precision-GI motorized endoscopic biopsy device. Limaca's endoscopic device is designed to obtain improved biopsy results for patients with suspected gastrointestinal cancers such as pancreatic, liver, and other GI-related and adjacent organs cancers and illnesses. The Precision-GI TPT grant is for up to three years beginningJanuary 1, 2025, thus supporting patient access to Limaca's new and innovative technology; previously, Precision-GI was granted the FDA's Breakthrough Device Designation in 2022 and received clearance by the U.S. Food and Drug Administration  inAugust 2023.Limaca's Precision-GI performed its first U.S.-based cases in September 2024 and is now commencing U.S. market en","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","TRNLY":"The Trendlines Group Ltd.","BK6516":"银行与投资服务概念","BK4585":"ETF&股票定投概念","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","CMS":"CMS能源","BK6052":"资产管理与托管银行","BK4588":"碎股","BK4208":"复合型公用事业","42T.SI":"趋势线","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC"},"translate_title":"Limaca的Precision-GI™获得CMS过渡传递(TPT)付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMS":1,"TRNLY":1,"42T.SI":0.9},"content_text":"Precision-GI™ FDA Designated Breakthrough product and FDA cleared semi-automated motorized endoscopic biopsy device entering U.S. market \nYOKNEAM, Israel, Nov. 7, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Limaca Medical Ltd. (\"Limaca\")'s Precision-GI™ motorized endoscopic biopsy device. Limaca's endoscopic device is designed to obtain improved biopsy results for patients with suspected gastrointestinal cancers such as pancreatic, liver, and other GI-related and adjacent organs cancers and illnesses. The Precision-GI™ TPT grant is for up to three years beginning January 1, 2025, thus supporting patient access to Limaca's new and innovative technology; previously, Precision-GI™ was granted the FDA's Breakthrough Device Designation in 2022 and received clearance by the U.S. Food and Drug Administration (FDA) in August 2023.\n\"Receiving TPT approval for our Precision-GI™ product is a major accomplishment for Limaca, enabling greater patient access to the breakthrough device, standardizing higher quality outcomes for these critical endoscopic biopsy procedures, and reducing repeat procedures for patients anxiously awaiting diagnostic results for suspected pancreatic and other GI cancers,\" said Limaca's CEO Assaf Klein. \"Very few products are granted TPT, and even fewer achieve both TPT and the FDA's Breakthrough designation. We are proud of these achievements and deeply pleased that the CMS TPT grant will enable broad patient access to Precision-GI.\"\nThe purpose of the TPT program is to support access to newly approved innovative technologies where the costs to adopt them may otherwise inhibit patient access. The TPT program reduces barriers for Medicare beneficiaries to access critical healthcare innovations shortly after products receive FDA approval by providing hospitals with additional payments to cover their costs, while allowing CMS to collect necessary cost data to determine future outpatient payments.\nEndoscopic biopsy is a mainstay diagnostic procedure performed with standard manually operated needles threaded through the working channel of the endoscopic ultrasound (EUS) device to visualize and access the target suspect lesion. Due to Precision-GI's motorized, automated, rotating cutting mechanism, much better quality tissue can be taken, with less blood content, in a single pass, saving critical procedure time and effort. A major benefit for patients over current endoscopic biopsy devices is the ability to consistently obtain superior volume and quality tissue acquisition needed for histopathologic and molecular analysis along with a high quality outcome, and standardization across a broad variation of physician skill levels.\nLimaca's Precision-GI performed its first U.S.-based cases in September 2024 and is now commencing U.S. market entry. A total of 510,992 new cases of pancreatic cancer were recorded around the world in 2022, with some of the highest rates occurring in Japan, USA, Germany, UK, and France - all between 8.0 - 9.8 per ASR (age standardized rates)[1]. Precision-GI is additionally working toward Japan's PMDA clearance and market entry along with its partner HekaBio. \n[1] World Cancer Research Fund Internationalhttps://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/\nAbout Limaca Medical\nLimaca Medical Ltd. is a privately held Israel-based company dedicated to improving endoscopic biopsy results for patients facing potentially life-threatening cancers. The company is funded by the Israeli Innovation Authority, Agriline, The Trendlines Group, Ltd. (SGX: 42T) (OTCQX: TRNLY) and additional medical device veterans in the U.S. Israel, and Japan. Partnerships include HekaBio, a Japan-based healthcare innovation commercialization company.\nContact:\nAssaf Klein, CEOAssaf@limaca-medical.com\n View original content:https://www.prnewswire.com/news-releases/limacas-precision-gi-granted-cms-transitional-pass-through-tpt-payment-302298613.html\nSOURCE Limaca Medical","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481902628"}